Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease

Myrte K. Neijenhuis, Tom J G Gevers, Marie C Hogan, Patrick Sequeira Kamath, Titus F M Wijnands, Ralf C P M van den Ouweland, Marie E. Edwards, Jeff A Sloan, Wietske Kievit, Joost P H Drenth

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Treatment of polycystic liver disease (PLD) focuses on symptom improvement. Generic questionnaires lack sensitivity to capture PLD-related symptoms, a prerequisite to determine effectiveness of therapy. We developed and validated a disease-specific questionnaire that assesses symptoms in PLD (PLD-Q). We identified 16 PLD-related symptoms (total score 0-100 points) by literature review and interviews with patients and clinicians. The developed PLD-Q was validated in Dutch (n = 200) and United States (US; n = 203) PLD patients. We assessed the correlation of PLD-Q total score with European Organization for Research and Treatment of Cancer (EORTC) symptom scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume. To test discriminative validity, we compared PLD-Q total scores of patients with different PLD severity stages (Gigot classification) and PLD-Q total scores of PLD patients with general controls and polycystic kidney disease patients without PLD. Reproducibility was tested by comparing original test scores with 2-week retest scores. In total, 167 Dutch and 124 US patients returned the questionnaire. Correlation between PLD-Q total score and EORTC symptom scale (The Netherlands [NL], r = 0.788; US, r = 0.811) and global health VAS (NL, r = −0.517; US, r = −0.593) was good. There was no correlation of PLD-Q total score with liver volume (NL, r = 0.138; P = 0.236; US, r = 0.254; P = 0.052). Gigot type III individuals scored numerically higher than type II patients (NL, 46 vs. 40; P = 0.089; US, 48 vs. 36; P = 0.055). PLD patients scored higher on the PLD-Q total score than general controls (NL, 42 vs. 17; US, 40 vs. 13 points) and polycystic kidney disease patients without PLD (22 points). Reproducibility of PLD-Q was excellent (NL, r = 0.94; US, 0.96). Conclusion: PLD-Q is a valid, reproducible, and sensitive disease-specific questionnaire that can be used to assess PLD-related symptoms in clinical care and future research. (Hepatology 2016;64:151–160).

Original languageEnglish (US)
Pages (from-to)151-160
Number of pages10
JournalHepatology
Volume64
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Netherlands
Surveys and Questionnaires
Polycystic liver disease
Polycystic Kidney Diseases
Visual Analog Scale
Liver
Gastroenterology
Therapeutics
Research
Neoplasms
Interviews
Global Health

ASJC Scopus subject areas

  • Hepatology

Cite this

Neijenhuis, M. K., Gevers, T. J. G., Hogan, M. C., Kamath, P. S., Wijnands, T. F. M., van den Ouweland, R. C. P. M., ... Drenth, J. P. H. (2016). Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease. Hepatology, 64(1), 151-160. https://doi.org/10.1002/hep.28545

Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease. / Neijenhuis, Myrte K.; Gevers, Tom J G; Hogan, Marie C; Kamath, Patrick Sequeira; Wijnands, Titus F M; van den Ouweland, Ralf C P M; Edwards, Marie E.; Sloan, Jeff A; Kievit, Wietske; Drenth, Joost P H.

In: Hepatology, Vol. 64, No. 1, 01.07.2016, p. 151-160.

Research output: Contribution to journalReview article

Neijenhuis, MK, Gevers, TJG, Hogan, MC, Kamath, PS, Wijnands, TFM, van den Ouweland, RCPM, Edwards, ME, Sloan, JA, Kievit, W & Drenth, JPH 2016, 'Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease', Hepatology, vol. 64, no. 1, pp. 151-160. https://doi.org/10.1002/hep.28545
Neijenhuis, Myrte K. ; Gevers, Tom J G ; Hogan, Marie C ; Kamath, Patrick Sequeira ; Wijnands, Titus F M ; van den Ouweland, Ralf C P M ; Edwards, Marie E. ; Sloan, Jeff A ; Kievit, Wietske ; Drenth, Joost P H. / Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease. In: Hepatology. 2016 ; Vol. 64, No. 1. pp. 151-160.
@article{6d850ed1006b4e25a86b4721fdfac69d,
title = "Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease",
abstract = "Treatment of polycystic liver disease (PLD) focuses on symptom improvement. Generic questionnaires lack sensitivity to capture PLD-related symptoms, a prerequisite to determine effectiveness of therapy. We developed and validated a disease-specific questionnaire that assesses symptoms in PLD (PLD-Q). We identified 16 PLD-related symptoms (total score 0-100 points) by literature review and interviews with patients and clinicians. The developed PLD-Q was validated in Dutch (n = 200) and United States (US; n = 203) PLD patients. We assessed the correlation of PLD-Q total score with European Organization for Research and Treatment of Cancer (EORTC) symptom scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume. To test discriminative validity, we compared PLD-Q total scores of patients with different PLD severity stages (Gigot classification) and PLD-Q total scores of PLD patients with general controls and polycystic kidney disease patients without PLD. Reproducibility was tested by comparing original test scores with 2-week retest scores. In total, 167 Dutch and 124 US patients returned the questionnaire. Correlation between PLD-Q total score and EORTC symptom scale (The Netherlands [NL], r = 0.788; US, r = 0.811) and global health VAS (NL, r = −0.517; US, r = −0.593) was good. There was no correlation of PLD-Q total score with liver volume (NL, r = 0.138; P = 0.236; US, r = 0.254; P = 0.052). Gigot type III individuals scored numerically higher than type II patients (NL, 46 vs. 40; P = 0.089; US, 48 vs. 36; P = 0.055). PLD patients scored higher on the PLD-Q total score than general controls (NL, 42 vs. 17; US, 40 vs. 13 points) and polycystic kidney disease patients without PLD (22 points). Reproducibility of PLD-Q was excellent (NL, r = 0.94; US, 0.96). Conclusion: PLD-Q is a valid, reproducible, and sensitive disease-specific questionnaire that can be used to assess PLD-related symptoms in clinical care and future research. (Hepatology 2016;64:151–160).",
author = "Neijenhuis, {Myrte K.} and Gevers, {Tom J G} and Hogan, {Marie C} and Kamath, {Patrick Sequeira} and Wijnands, {Titus F M} and {van den Ouweland}, {Ralf C P M} and Edwards, {Marie E.} and Sloan, {Jeff A} and Wietske Kievit and Drenth, {Joost P H}",
year = "2016",
month = "7",
day = "1",
doi = "10.1002/hep.28545",
language = "English (US)",
volume = "64",
pages = "151--160",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease

AU - Neijenhuis, Myrte K.

AU - Gevers, Tom J G

AU - Hogan, Marie C

AU - Kamath, Patrick Sequeira

AU - Wijnands, Titus F M

AU - van den Ouweland, Ralf C P M

AU - Edwards, Marie E.

AU - Sloan, Jeff A

AU - Kievit, Wietske

AU - Drenth, Joost P H

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Treatment of polycystic liver disease (PLD) focuses on symptom improvement. Generic questionnaires lack sensitivity to capture PLD-related symptoms, a prerequisite to determine effectiveness of therapy. We developed and validated a disease-specific questionnaire that assesses symptoms in PLD (PLD-Q). We identified 16 PLD-related symptoms (total score 0-100 points) by literature review and interviews with patients and clinicians. The developed PLD-Q was validated in Dutch (n = 200) and United States (US; n = 203) PLD patients. We assessed the correlation of PLD-Q total score with European Organization for Research and Treatment of Cancer (EORTC) symptom scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume. To test discriminative validity, we compared PLD-Q total scores of patients with different PLD severity stages (Gigot classification) and PLD-Q total scores of PLD patients with general controls and polycystic kidney disease patients without PLD. Reproducibility was tested by comparing original test scores with 2-week retest scores. In total, 167 Dutch and 124 US patients returned the questionnaire. Correlation between PLD-Q total score and EORTC symptom scale (The Netherlands [NL], r = 0.788; US, r = 0.811) and global health VAS (NL, r = −0.517; US, r = −0.593) was good. There was no correlation of PLD-Q total score with liver volume (NL, r = 0.138; P = 0.236; US, r = 0.254; P = 0.052). Gigot type III individuals scored numerically higher than type II patients (NL, 46 vs. 40; P = 0.089; US, 48 vs. 36; P = 0.055). PLD patients scored higher on the PLD-Q total score than general controls (NL, 42 vs. 17; US, 40 vs. 13 points) and polycystic kidney disease patients without PLD (22 points). Reproducibility of PLD-Q was excellent (NL, r = 0.94; US, 0.96). Conclusion: PLD-Q is a valid, reproducible, and sensitive disease-specific questionnaire that can be used to assess PLD-related symptoms in clinical care and future research. (Hepatology 2016;64:151–160).

AB - Treatment of polycystic liver disease (PLD) focuses on symptom improvement. Generic questionnaires lack sensitivity to capture PLD-related symptoms, a prerequisite to determine effectiveness of therapy. We developed and validated a disease-specific questionnaire that assesses symptoms in PLD (PLD-Q). We identified 16 PLD-related symptoms (total score 0-100 points) by literature review and interviews with patients and clinicians. The developed PLD-Q was validated in Dutch (n = 200) and United States (US; n = 203) PLD patients. We assessed the correlation of PLD-Q total score with European Organization for Research and Treatment of Cancer (EORTC) symptom scale, global health visual analogue scale (VAS) of EQ-5D, and liver volume. To test discriminative validity, we compared PLD-Q total scores of patients with different PLD severity stages (Gigot classification) and PLD-Q total scores of PLD patients with general controls and polycystic kidney disease patients without PLD. Reproducibility was tested by comparing original test scores with 2-week retest scores. In total, 167 Dutch and 124 US patients returned the questionnaire. Correlation between PLD-Q total score and EORTC symptom scale (The Netherlands [NL], r = 0.788; US, r = 0.811) and global health VAS (NL, r = −0.517; US, r = −0.593) was good. There was no correlation of PLD-Q total score with liver volume (NL, r = 0.138; P = 0.236; US, r = 0.254; P = 0.052). Gigot type III individuals scored numerically higher than type II patients (NL, 46 vs. 40; P = 0.089; US, 48 vs. 36; P = 0.055). PLD patients scored higher on the PLD-Q total score than general controls (NL, 42 vs. 17; US, 40 vs. 13 points) and polycystic kidney disease patients without PLD (22 points). Reproducibility of PLD-Q was excellent (NL, r = 0.94; US, 0.96). Conclusion: PLD-Q is a valid, reproducible, and sensitive disease-specific questionnaire that can be used to assess PLD-related symptoms in clinical care and future research. (Hepatology 2016;64:151–160).

UR - http://www.scopus.com/inward/record.url?scp=84976463730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976463730&partnerID=8YFLogxK

U2 - 10.1002/hep.28545

DO - 10.1002/hep.28545

M3 - Review article

C2 - 26970415

AN - SCOPUS:84976463730

VL - 64

SP - 151

EP - 160

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -